Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 20/20 | 0.76 |
| ▸ | FGFR3 | P22607 | 19/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 17/20 | 0.76 |
| ▸ | FGFR4 | P22455 | 16/20 | 0.76 |
| ▸ | KDR | P35968 | 10/20 | 0.76 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17036024 | 0.86 | FGFR2 (1.00) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL20457009 | 0.85 | FGFR2 (0.56) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL17035956 | 0.85 | FGFR3 (0.74) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL17035955 | 0.85 | FGFR3 (0.77) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL17035957 | 0.85 | FGFR3 (0.77) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL21727998 | 0.80 | FGFR2 (0.86) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL17036026 | 0.76 | FGFR3 (0.72) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL17036022 | 0.74 | FGFR3 (1.00) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL16132976 | 0.73 | FGFR2 (0.44) | FGFR2FGFR3FGFR1FGFR4KDR | |
| SCHEMBL17036025 | 0.72 | FGFR2 (0.75) | FGFR2FGFR3FGFR1FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737544-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| US-20160213677-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| US-9303030-B2 | Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-05 | — | — | US | disclosed |
| US-20150239883-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239883-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | FGFR2 2213/4885FGFR3 2473/4885FGFR1 1982/4885 |
| US-20160213677-A1 | NEW COMPOUNDS | NTPCR, MT-ND5, NQO1 | FGFR2 2213/4885FGFR3 2473/4885FGFR1 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.